Drug firm Sharon Bio-Medicine today said the US health regulator has inspected one of its formulation plants in Dehradun.
"In the last week one of our formulation plants at Dehradun in Uttarakhand has been inspected and audited by US Food and Drug Administration (USFDA) officials," Sharon Bio-Medicine said in a BSE filing.
USFDA had inspected company's manufacturing facility at Taloja near Navi Mumbai last month, it added.
"This is our second plant which has been inspected and audited by USFDA officials in the last two months. First plant at Taloja near Navi Mumbai was inspected and audited in the first week of July 2015," the company said.
Last month, USFDA had issued a warning letter to the firm for failing to pay generic drug user fee by its owner for three years starting 2013, saying its Dehradun-based facility would be barred from shipping products to the US if the dues are not cleared.
Sharon Bio-medicine shares were trading at Rs 21.30, up 20 per cent, apiece on the BSE.
